Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

GLP-1s have been heralded for their ability to suppress appetite but did you know that GLP-1 is a natural hormone you can stimulate without injections.

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (NASDAQ: VKTX), ...

Target RWE, a leader in real-world evidence solutions in liver disease, presented important research on the use of ...

Terns Pharmaceuticals Inc.’s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an ...

Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

Novo Nordisk is working to accelerate the launch of its weight-loss drug Wegovy in India, concerned about lagging behind Eli ...

The future of obesity treatment looks highly promising with the development of next generation therapies. There are currently 79 clinical stage programmes across at least 41 unique mechanisms of ...

(HealthDay News) — The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy) and ...

With deaths from obesity-related heart disease reportedly increasing by 180% over the past 20 years, more research is being done to learn how GLP-1 medications such as Ozempic, Wegovy, Mounjaro and ...